Deal value in the healthcare industry fell dramatically at the start of the year as the sector contended with significant social and financial disruption, in addition to an increasingly volatile geopolitical context for deals.

However, on the whole, the sector appears to be emerging from the crisis relatively resilient. The pandemic has been a catalyst for innovation; demand for telemedicine and remote monitoring has soared; the regulatory framework has been transformed, and investors continue to take a keen interest in a sector of increasing social, economic and political significance.

How is an industry notorious for its complexity when it comes to deals, responding to the crisis and attempting to improve the way deals are identified and executed? In what ways are the regulatory and legislative context for deals in the sector changing? How are healthcare companies, disrupters and investors partnering in new ways to accelerate innovation?

The Financial Times, in partnership with Baker McKenzie, are delighted to host this high-level virtual discussion bringing together healthcare corporations, technology companies, and financial investors to explore the ways in which M&A will reshape the sector and fast-track innovation.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice